Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b randomized double-blind placebo-controlled study of guselkumab in active psoriatic arthritis
MOH_2021-09-12_009915Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Started Sep 2021; status: recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on MOH_2021-09-12_009915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-12_009915.